BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus

Core Viewpoint - BioMarin Pharmaceutical Inc. has successfully acquired Amicus Therapeutics for nearly $5 billion, which is expected to enhance its commercial portfolio and revenue growth significantly. Group 1: Acquisition Details - BioMarin entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share, representing a 33% premium over Amicus's closing price on December 18 [2] - The acquisition will be funded through cash on hand and approximately $3.7 billion of non-convertible debt financing [3] Group 2: Financial Impact - The acquisition is anticipated to support BioMarin's long-term compound annual growth rate (CAGR) through 2030, with the two new treatments generating combined net product revenues of $599 million in the past year [4] - The transaction is expected to accelerate revenue growth and strengthen BioMarin's financial outlook, being accretive to Non-GAAP Diluted EPS within the first 12 months post-closure [5] Group 3: Market Performance - Following the announcement of the acquisition, BioMarin's stock surged 17.71% to close at $61.15, marking its third consecutive day of gains [1]